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Abstract
Acute hyperglycemia can impair vascular endothelial function in non-diabetic subjects in
addition to diabetic patients. Decreased endothelial-derived nitric oxide (NO)
bioavailability and increased concentrations of reactive oxygen species (ROS), such as
superoxide (SO) and hydrogen peroxide (H202), are the major charactetistics of vascular
endothelial dysfunction. Normally, vascular endothelial function depends on NO
production from coupled endothelial NO synthase (eNOS) in the presence of 5,6,7,8tetrahydrobiopterin (BH4). By contrast, 7,8-dihydrobiopterin (BH2, Oxidized form of
BH4) and/or lack ofL-arginine (coupled eNOS substrate) causes eNOS uncoupling to
produce SO, which can be quickly converted to H202. The role of eNOS uncoupling in
acute hyperglycemia induced vascular dysfunction in vivo is unclear. In this study; we
hypothesized that acute hyperglycemia (200 mg/dL) would increase H202 and decrease
NO release in blood relative to saline control. By contrast, BH4 or L-arginine would
attenuate the acute hyperglycemia-induced blood NO and H20 2 changes. However, BH2
will exacerbate the acute hyperglycemia-induced blood NO and H202levels. To test the
hypothesis, blood NO or H20 2 levels were measured simultaneously using calibrated NO
or H20 2 micro sensors ( 100 )lm; WPI Inc.) by placing them into the femoral veins of male
Sprague-Dawley rats. The electrical traces from microsensors were recorded at baseline
and throughout 3 hours of infusion with saline or 20% D-glucose with or without a drug
(BH4,BH2, or L-arginine) and converted into a concentration based on a calibration curve.
Acute hyperglycemia (200 mg/dL by i.v. 20% D-glucose) significantly increased H20 2
(n=6) and reduced NO (n=6) blood levels in comparison to the saline group (n=7,
p<0.05). BH2 (MW=239.23 g/mol, 4mg/kg) exacerbated hyperglycemia,- induced
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increased H20 2 levels (n=7) and decreased NO levels (n=6) (p<0.05). By contrast, BH4
(n=6, MW=314.20 glmol , 6.5mglkg), significantly reduced blood H20 2 levels and
increased blood NO levels during acute hyperglycemia compared to saline control
(p<0.05). Moreover, L-arginine (MW=210.66 glmol, 600mglkg) had similar effects on

H20 2 (n=5) and NO (n=6) blood levels as BH4, showing significant reduction of blood
H202 and enhancement ofblood NO compared to saline control (p<0.05). In summary,
uncoupled eNOS serves as a significant mechanism mediating acute hyperglycemiainduced vascular dysfunction and oxidative stress. Therefore, promotion of eNOS
coupling may be effective in protecting vascular endothelial function from hyperglycemic
insult.

v

Table of Contents
List of Figures ................................................................................................................... vii
Acknowledgments .............................. .............................................................................. viii
Introduction ................................ .......................................................................................... ]
Methods ........... ..................................... ........................................................ ... ................... i S
Results ............ .. ............ ......... ....... ......... ............ ...... .. .................... .....................................25
Discussion .............................. .... ................................ ............. .................. .................... ..... 33
References .... .................................. .......... .................. .............. ...... ................ ... .................48

VI

List of Figures

Figure 1:

Coupled and uncoupled eNOS activity ........................................................... 8

Figure 2:

The production of NO in vasculature and its major physiological and
pathophysiological effects ................................................................................ 9

Figure 3:

The catheterization of the jugular vein as anow indicates .......................... ... 20

Figure 4:

NO and H202 microsenors in the femoral veins ..... ............. ........................ .. 21

Figure 5:

The comparison ofblood glucose levels among saline and 20% D-glucose
hyperglycemia infusion groups with or without the drugs throughout 3 hours
experimental time ........................................................... ................................27

Figure 6:

The comparison of blood NO levels relative to baseline among saline, 20%
D-glucose, 20% D-glucose with BH4, 20% D-glucose with BH2, and 20% Dglucose with L-arginine ..... ........... .................................................................. 29

Figure 7:

The comparison ofblood NO levels relative to saline group among 20% Dglucose, 20% D-glucose with BH4, 20% D-glucose with BH2, and 20% Dglucose with L-arginine .......... ........................ .. ..... ........................................ 29

Figure 8:

The comparison of blood H202 levels relative to baseline among saline, 20%
D-glucose, 20% D-glucose with BH4, 20% D-glucose with BH2, and 20% Dglucose with L-arginine .... ........ .. ......... ..................... ....... ............ ................... 32

Figure 9:

The comparison of blood H202 levels relative to saline among 20% Dglucose, 20% D-glucose with BH4, 20% D-glucose with BH2, and 20% Dglucose with L-arginine ....................... ...........................................................32

Figure 10: A representation of the vicious cycle oxidative stress under hyperglycemia
conditions .......................................................................................................35

Vll

Acknowledgments
I would like to thank the following people for their contributions to my thesis and
research:

Qian Chen, Ph.D., Research Assistant Professor of Department of Bio-Medical Sciences,
Philadelphia College of Osteopathic Medicine (PCOM), Thesis Advisor
Lindon Howard Young, Ph.D., Professor of Department ofBio-Medical Sciences,
PCOM, Thesis Committee Member
Charlotte Greene, Ph.D., Professor of Department ofBio-Medical Sciences, PCOM,
Thesis Committee Member
Dr. Marcus Bell, Director of M.S. , Professor of Bio-Medical Sciences, PCOM
James Wood, Director of Laboratory Animal Resources
Tyler Galbreath, Alexandra Lopez, Regina Ondrasik, Hung Pham, Issachar Devine,
Graduate Students at PCOM
Center for Chronic Disorders of Aging and the Department of Bio-Medical Sciences,
PCOM

Introduction
Hyperglycemia and Vascular Complications

Hyperglycemia has been observed in association with many diseases such as
diabetes, prediabetes, metabolic syndromes, and some post-surgery complications ( 13,
14, 28, 87). There is substantial evidence indicating that both acute and chronic
hyperglycemia have negative effects on vascular function and are closely related to the
development and progression of microvascular, neurologic, and macrovascular
complications. The underlying mechanisms of hyperglycemia induced vascular/organ
damage, however, are complex. It has been suggested that vascular endothelial
dysfunction is a critical step in initiating the vascular damage. Therefore, it is vital to
identify the mechanisms mediating hyperglycemia induced vascular endothelial
dysfunction.

I. Clinical Hyperglycemic Conditions
Elevated fasting blood glucose is one of the approved criterion for diagnosing
diabetes mellitus approved by the American Diabetes Association (ADA). This is
measured by analyzing the plasma or serum glucose levels after at least 8 hours of fasting
(usually done overnight). The range of n01mal human fasting plasma or serum glucose
levels is between 70 and 100 mg/dL. A plasma glucose level of 126 mg/dL or greater
indicates hyperglycemia. lfthe hyperglycemia occurs on more than one occasion after at
least 8 hours of fasting, a diagnosis of diabetes mellitus is made. Prediabetes is defined
when the fasting plasma glucose levels remain between 100 mg/dL and 125 mg/dL.
Prediabetes can increase the risk for diabetes (30).
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An oral glucose tolerance test (OGTI) is another method used to diagnose
diabetes. For this test an adult is given a loading dose of75 g of glucose in 300 ml of
water. Blood samples are assayed for plasma glucose at the 0 minute and 120 minute
mark after the loading dose is ingested. If the patient' s blood glucose levels are greater
than 200 mg/dL after the 120 minute mark a diagnosis of diabetes is made. An OGTI is
considered normal if the two-hour blood glucose value falls below 140 mg/dL. If the twohour postprandial blood glucose levels are between 140-199 m g/dL the patient is
considered to have impaired glucose tolerance.
When the blood glucose is about 200 mg/dL (i.e. mild hyperglycemia), patients
begin to exhibit the symptoms of hyperglycemia including excessive thirst, polyuria,
headaches, fatigue and blutTed vision (27; 28; 30). Diabetic ketoacidosis (DKA) is a
complication of diabetes mellitus that occurs when the body cannot use glucose as a fuel
supply due to an insufficient amount of insulin in the body, and results in the breakdown
of body fat for energy and, thus, an accumulation of ketones. DKA affects patients with
serum glucose levels over 300 mg/dL. This severe hyperglycemia, if left untreated, can
lead to coma and death. When blood glucose is 600 mg/dL or higher it can induce
hyperglycemic hyperosmolar syndrome (HH S), an increase in blood viscosity due to the
excess glucose in the blood and dehydration, which may result in coma and even death
(52).

2. Acute Hyperglycemia in Non-Diabetic Subjects
In non-diabetic subjects, blood glucose levels can increase under some conditions
such as following a high glucose meal (i.e., oral glucose tolerance test), stress, post-
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surgery, certain medications, and critical illness (22; 25; 70). Fasting plasma glucose and
postprandial glucose levels/OGTI often have been used clinically to indicate an acute
hyperglycemia level (30).
Stress hyperglycemia is an acute, transient hyperglycemia caused by severe
illness or post-surgery in patients/individuals without pre-existing diabetes (39). There is
evidence that stress hyperglycemia in critically ill and preoperative patients can serve as
an independent marker of complications such as: infection, a slower recovety time, and
higher mortality (22; 25; 70). When hyperglycemia is uncontrolled it can lead to
hypokalemia, hyponatremia, arrhytlunias and an increased risk of ischemic brain injury
(36). Hyperglycemia may also increase the risk of post-surgical infections in patients by
impairing leukocyte functions including: reduced granulocyte adherence, impaired
phagocytosis, delayed chemotaxis, depressed bactericidal capacity, and decreased
neutrophil function (41; 67). Because of all of the consequences of hyperglycemia, it is
important to make sure that patients maintain nonnal blood glucose levels at all times. It
has been found that maintaining blood glucose under 110 mg/dL significantly reduces
mortality and morbidity among critically ill patients both surgical and non-surgical
treated critically ill patients (29).
Some studies have linked the role of acute hyperglycemia to the development of
vascular complications in non-diabetic individuals (27). Fmthennore, it has been shown
that high dietary glucose consumption and postprandial hyperglycemia are associated
with an increased tisk of cardiovascular disease, even in the absence of clinically
diagnosed diabetes (13). Hanefeld et al. have shown a link between postprandial
hyperglycemia levels in nondiabetic patients and the incidence of increased intima-
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media thickness (IMT), which is a generally accepted marker of early atherosclerosis
(3 7). In a study containing 403 participants, Hanefeld noted that the carotid IMT was
significantly increased in both the top quintile of2 hour post prandial plasma glucose and
peak plasma glucose concentration (3 7). Further indications were detived from
pathophysiological studies which indicated that increased post prandial glucose levels are
associated with increased production and difficult removal of triglyceride-rich
lipoproteins, impaired fibrinolysis, and oxidative stress. These observations led Hanefeld
et al. to suggest that postprandial hyperglycemia in conjunction with oxidative stress
could have destmctive effects on the arterial wall and may accelerate atherosclerosis (37).
It also has been suggested that many cardiovascular risk factors are modified due to the

increased postprandial glucose. One of the primary mechanisms could be that acute
hyperglycemia may cause the overproduction of free radicals overwhelming the
antioxidant mechanisms resulting in oxidative stress, which favors the development of
vascular endothelial dysfunction and disease (20).

3. Chronic Hyperglycemia/Diabetes
Diabetes mellitus is the most common chronic metabolic disease and a major
source causing morbidity and mmtality (64). Diabetes mellitus is charactetized by
hyperglycemia due to a total or relative lack of insulin secretion and/or insulin resistance
associated with different vascular complications (I ; 3). In the year 2000, there were
approximately 171 million diabetics and the prevalence is expected to increase up to 366
million globally by 2030 (85). As of today, the World Health Organization estimates that
there are 347 million people worldwide who have diabetes ( 18). The long tetm prognosis
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of those with diabetes remains poor due to the microvascular and macro vascular
complications resulting from clu·onic hyperglycemia.
Microvascular complications from diabetes include retinopathy, nephropathy, and
neuropathy. In 2011, the National Center for Clu·onic Disease Prevention and Health
Promotion published data showing that diabetes is the leading cause of new cases of
blindness and kidney failure among adults. Furthermore, about 60- 70% of people with
diabetes have mild to severe forms of nervous system damage. Moreover, greater than
60% ofnontraumatic lower-limb amputations occur in people with diabetes (1). In terms
of macrovascular complications, diabetes is characterized by a high prevalence of
cardiovascular diseases (14). Diabetics have two to four times higher heatt disease death
rates than non-diabetic individuals (1 ). About 65% of patients with type II diabetes die
from complications linked to heart disease or stroke (60; 68).
Postprandial hyperglycemia has been found to play an important role in the
pathogenesis of vascular complications and cardiovascular disease (CVD) in diabetes.
The study conducted by Meigs, Nathan et al showed that fasting hyperglycemia and 2
hour post-challenge hyperglycemia independently increase the risk for CVD, even after
accounting for standard nonglycemic risk factors (59). Additionally, the " DECODE"
study (Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria) in Europe
indicated that the 2-hour glucose criterion alone increased the mortality risk of
cardiovascular disease regardless of fasting plasma glucose levels (2). Postprandial
hyperglycemia in a subset of type II diabetic patients has also been associated with
myocardial perfusion defects, which might constitute a very early phase of the
atherogenic process in the coronary circulation (73). Similarly, other studies have shown
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that acute hyperglycemia increases the stiffness of intetmediate-sized arteries and
resistance arteties in young patients with type 1 diabetes (33).

Hyperglycemia and Vascular Endothelial Dysfunction:
It is vital to preserve the homeostasis of vascular endothelium in its resting state

for proper blood perfusion into tissues and organs. Vascular endothelium can react with
various physical and chemical stimuli and is involved in the pathogenesis of different
diseases, such as ischemia/reperfusion injury, hyperglycemia, diabetes, and infectious
diseases (65; 69). Hyperglycemia can disturb vascular endothelium homeostasis, induce
vascular endothelial dysfunction, and initiate the cascade of vascular based organ
dysfunction.

1. Normal Vascular Endothelial Function
The endothelium is composed of a monolayer of endothelial cells and lines the
entire vascular system. Endothelial cell structure and functional integrity are essential in
the maintenance of circulatory function via the vessel wall, which serves as a semipermeable ban·ier and controls the transfer of small and large molecules (76). The
vascular endothelium is nmmally maintained at a resting state and acts as a chief
regulator of vascular homeostasis (84). Endothelial cells can produce and release a
vatiety of vasoactive substances including prostacyclin and nitric oxide in response to
chemical stimuli and alterations in hemodynamic forces (31 ; 45; 76). Consequently,
under standard conditions vascular endothelial cells maintain an antithrombotic surface
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which facilitates adequate blood flow by regulating thrombosis, thrombolysis, platelet
and leukocyte adherence, and vascular tone (31; 76; 92).

Nitric Oxide
Nittic Oxide (NO), a potent endogenous vasodilator, is the most important
vasoactive substance produced by the vascular endothelium (19). It serves as a
vasodilator to all blood vessels in the body and reduces inflammation. Under normal
physiological conditions, endothelial derived NO is produced by the membrane bound
enzyme endothelial nitric oxide synthase (eNOS) . eNOS oxidizes the amino acid Larginine in a five electron oxidation step to form the intetmediate NG-hydroxy-L-arginine

(34). Reduced nicotinamide-adenine-dinucleotide phosphate (NADPH) and molecular
oxygen are two impmtant substrates, while BH4 is an essential cofactor in this reaction
(42; 82). The oxygenase domain of eNOS contains a BH4 prosthetic group. By donating
a single electron, BH4 activates heme-bound oxygen which is then recaptured to enable
NO release (94). It has been indicated that L-arginine and BH4 are two critical factors in
stabilizing the dimerization of the eNOS structure for electron transfer and NO
production. Accordingly, eNOS normally produces NO in the presence of an essential
cofactor, BH4, by facilitating the reduction of molecular oxygen to L-arginine oxidation
and generation of L-citrulline. This reaction is refetTed to as eNOS coupling (See Figure
1) (72).
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Coupled eNOS

Uncoupled eNOS

Figure 1. Coupled and uncoupled eNOS activity. Endothelial NOS coupling occurs using BH4 as
a cofactor duti ng a physiological condition allowing the reaction to produce NO and L-citrulline
from L-arginine /NADPH/02. When uncoupled, eNOS uses BI-h as a cofactor to produce SO.
Pi cture is adapted from (72).

The synthesis and release ofNO occur in response to stimuli acting on the
endothelial cell surface. This is dependent on the increase in intracellular calcium levels
resulting in calmodulin formation, which leads to displacing caveolin and activating the
eNOS ( 44). The release of NO can be stimulated by physical forces, such as the shear
stress of flowing blood, and neurohumoral factors, such as acetylcholine or bradykinin
(82). As a strong and lipophilic gas NO is able to penneate cell membranes freely and
diffuse toward smooth muscle cells and into the vascular lumen (See figure 2) (84).
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Figure 2. The production of NO in vasculature and its major physiological and
pathophysiological effects. Picture is adapted from (61).

NO exerts its etfect in smooth muscle cells by binding to the prosthetic heme
group of the NO-sensitive guanylyl cyclase enzyme (4). Activated NO-sensitive guanylyl
cyclase (GC) results in an increased production of cyclic 3'5' guanosine monophosphate
(cGMP) from GTP (5). cGMP is an impmtant second messenger which results in the
activation of cGMP-dependent protein kinase, which further lead to the
dephosphorylation of myosin light chain kinase (MLCK). K+ channels have been shown
to be phosphorylated by cGMP-dependent protein kinase, leading to the membrane
h yperpolmization and reduction of intracellular Ca2+ ions. Together, these collective
processes result in the relaxation of smooth muscle cells (See figure 2) (44; 50).
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In addition to its function as a vasodilator, NO has numerous effects on the
cardiovascular system which include the reduction of small amounts of SO radicals, as
well as an inhibitory effect on platelet aggregation and smooth muscle cell proliferation
(47). NO plays an essential role in preventing neutrophil and platelet adhesion,
aggregation, and activation (See figure 2) (31 ). Kubes et al. demonstrated that inhibiting
the synthesis of NO production by using NG monomethyl-L-arginine (L-NMMA) and NG
nitro L-arginine methyl ester (L-NAME), analogues of L-arginine that inhibit NO
production, resulted in a 15-fold increase in leukocyte adherence and a significant
increase in transmigration of leukocytes in cat mesenteric postcapillary venules (46).
These transmigrated leukocytes can ultimately release SO, myeloperoxidase, elastase,
and lipases which can cause cell and tissue damage in pathology (48; 90). These results
show that endothelial-derived NO is a significant endogenous inhibitor ofleukocyteendothelial interactions and adhesion (46).
There are two other isofonns ofNOS enzyme in addition to eNOS. Each of the
NOS isofmms has specific functions. Neuronal NOS (nNOS) is found in the nervous
system as well as skeletal muscle, cardiac muscle and smooth muscle (89). nNOS
constitutes the predominant source ofNO in neurons and is localized to synaptic spines.
Inducible NOS (iNOS) is found in the immune system and utilized by macrophages,
neutrophils, and other inflammatory cells. iNOS expression increases during the
inflammatory process and some malignant transformations (27; 43). Neuronal NOS and
eNOS are constitutively expressed and Ca2 +/calmodulin-dependent. Both nNOS and
eNOS produce small amounts ofNO (i.e., nM range), which has precise actions on
adjacent cells (89). In contrast, iN OS is Ca2 +/ calmodulin independent and produces high
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levels ofNO (i.e., J..lM range) in response to inflammatory cytokines and other stimuli
(62).
As previously stated, NO diffuses into smooth muscle activating the NO-soluble
GC, however, the majority of the NO that does not diffuse abluminally reacts rapidly
with hemoglobin to fonn nitrate and methemoglobin if oxygenated, and ironnitrosylhemoglobin if deoxygenated. Approximately 20% of NO produced by eNOS in
the vasculature escapes inactivation by hemoglobin and becomes oxidized to nitrite
(N02-) in the plasma by a ceruloplasmin catalyzed reaction, and functions to modify
proteins and lipids to form low concentrations of N-nitrosamines, S-nitrosothiols
(RSNO), and nitrated lipids. Nitrite may also function as a stable vascular store ofNO
that can be enzymatically reduced to NO by deoxygenated hemoglobin along the
physiological oxygen and pH gradient (51).

Reactive O.>.y gen Species (R OS)
ROS are molecules derived from molecular oxygen including SO, H20 2, and the
hydroxyl radical CHO) (35). Some of the potential sources ofROS include uncoupled
eNOS, NADPH oxidases, xanthine oxidase, the cytochrome P-450 enzymes, the
mitochondrial electron transport chain, the arachidonic acid metabolizing enzymes
lipoxygenase and cycloxygenase, peroxidases, and other hemoproteins (1 0; 35). Under
normal conditions, ROS have beneficial effects at low concentrations and encompass
physiological roles in host defense mechanisms (against infectious agents) and in a
number of cellular signaling systems (87). Furthermore, a delicate balance exists between
the formation of these oxidizing substances and their effective removal by defensive
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antioxidant mechanisms under normal physiological conditions (31 ). As a very unstable
compound, SO has a half-life of seconds. Superoxide dismutase (SOD) convetts SO to
H202. Subsequently H202 is converted to water by catalase to facilitate its removal from
the body. Because of the half-life ofH202 is several minutes and more accurate to
measure, the measurement ofH202 will therefore serve as a good indicator ofblood SO
production (16).

2. Endothelial Dysfunction and Hyperglycemia
The dysfunction of vascular endothelium has been recognized as an essential
component in vascular/organ damage because it is a common and early feature (57; 71).
In much of the literature, endothelial dysfunction has been defined as the impairment of
endothelium-dependent vasorelaxation caused by the loss of NO bioactivity in vessel
walls (11). It also has been associated with increased oxidative stress (93). Highfrequency ultrasonographic imaging of the brachial artery is a noninvasive approach that
utilizes the ultrasound to measure blood vessel diameter and blood flow in order to assess
endothelium-dependent flow-mediated vasodilation (FMD) (14; 56).
Hyperglycemia reduces the bioavailability of NO resulting in the development of
vascular endothelial dysfunction (17). There is a great amount of evidence that suggests
that vascular endothelial dysfunction is one of earliest events induced by hyperglycemia.
The OGTT on healthy subjects with nonnal glucose tolerance, which simulates
postprandial hyperglycemia, resulted in a significant reduction in flow-mediated
endothelium-dependent vasodilation at 1 hour, and by 2 hour post challenge was restored
to the baseline (40). CmTespondingly, the postprandial hyperglycemia in relatively
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healthy subjects can acutely affect endothelium-dependent regulation of blood flow (81 ).
Furthermore, application ofBH4 to these healthy subj ects reverses postprandial
hyperglycemia-induced vascular endothelial dysfunction at the 1 hour mark (81).
Conversely, the recovery of the flow-mediated endothelium-dependent vasodilation
response post-challenge was greatly diminished in diabetic patients who have chronic
hyperglycemia (40).

Endothelial NOS and Hyperglycemia
As previously stated, eNOS coupling requires the presence of the substrate Larginine and cofactor BH4. Conversely, when L-arginine is insufficient or BH4 is
oxidized to BH2 which in turn reduces the ratio ofBH4 to BH2, eNOS becomes
" uncoupled" and uses molecular oxygen to produce SO instead ofNO (See Figure 1)
(17). While it is suggested that eNOS " uncoupling" can mediate vascul ar endothelial
dysfunction under hyperglycemia conditions, it is still uncet1ain that eNOS "uncoupling"
is attributed to the lack ofL-arginine substrate or the reduced BH4 to BH2 ratio (17).

Oxidative Stress under hyperglycemia
Oxidative stress usually refers to the process of cellular damage as a consequence
of the uncontrolled action ofROS (84). This damage occurs due to the imbalance
between the over formation of oxidizing agents (ROS) and reduced removal by
antioxidants in favor of ROS accumulation (31 ). Pathologies caused by SO are
unfavorable and well recognized (23). ROS such as SO have been shown to initiate cell
death programs such as apoptosis and cell necrosis. Additionally, they have been shown
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to impair vasodilatory responses of the vascular endothelium and oxidize proteins and
lipids, and damage DNA (31; 49). Moreover, SO can combine with NO and inactivate the
bioavailable NO at a rapid rate of6.7 x 109 mol/L- 1-s-1 (78). The new compound
produced is called peroxynitrite (ONOOt which is very cytotoxic and induces cell
damage by oxidizing BH4 to BH2. With a decreased BH4 to BH2 ratio, uncoupling of
eNOS results in an increased production of SO (See Figure 1). Subsequently, endothelial
dysfunction can be induced and serves as a feedback inhibition of NO production (31 ).
Levels ofROS, particularly SO, significantly increase when endothelial cells are
exposed to high glucose (28; 91). Studies have shown that systemic oxidative stress and
lipid oxidation occur under both acute and chronic hyperglycemic conditions (58). The
enzyme NADPH oxidase, in addition to uncoupled eNOS, serves as another important
source of SO production in vascular tissue. Under hyperglycemic conditions, protein
kinase C- beta (PKC- P) is activated which further induces NADPH oxidase activation to
produce the superoxide anion. PKC- p inhibitors have been shown to prevent the
hyperglycemia induced decrease in endothelium-dependent vasodilation (7). Moreover,
xanthine oxidase, NADPH oxidase ofneutrophils, and mitochondtial dysfunction also
serve as sources for the production of SO. Some studies have shown anti-oxidants, such
as vitamin C, attenuated the abnormality in endothelium-dependent vasodi lation caused
by hyperglycemia (6).
Vascular endothelial dysfunction can further initiate leukocyte-endothelial
interactions. Vascular endothelial adhesion molecules such as P-selectin, intercellular
adhesion molecule-1(ICAM-1), and vascular cell adhesion molecule-! (VCAM-1) are
upregulated to promote leukocyte rolling, adherence and transmigration (63).
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Furthermore, transmigrated leukocytes cause fmther inflammatory reactions by releasing
cytokines such as tumor necrosis factor-a (TNF-a) and interleukin- 1 (IL- l ) to recruit
more leukocytes, and by releasing proteases and ROS which can cause endothelial injury.
Organ and tissue damage can be induced from vascular endothelial dysfunction
associated inflammation (66).

Summary of Background and Hypothesis
It has been established that chronic hyperglycemia induces oxidative stress and
diminishes endotheli al-derived NO bioavailability, which are closely associated to
microvascular and m acrovascular complications of diabetes. Multiple studies suggest that
acute hyperglycemia, especially postprandial hyperglycemia, may increase oxidative
stress and cause vascular endothelial dysfunction in healthy individuals. Acute
hyperglycemic exposures that ranged from one to six hours impair endothelium
dependent vasodilatation and can cause acute oxidative stress in healthy nondiabetic
subjects (6 ; 79; 86). Furthetmore, various studies suggest that acute hyperglycemia can
decrease the BH4/BH2 ratio and increase asymmetric dimethylarginine concentrations.
The reduced BH4/BH2 ratio facilitates eNOS uncoupling. Asymmetric dimethylarginine
interferes with the L-arginine in the production of NO via eNOS. It has been suggested
that eNOS uncoupling is involved in the vascular function change resulting in decreased
NO bioavailability and increased ROS production in vivo in non-diabetic subjects,
respectively (17; 53).
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Conversely, in a study done by McNulty on nondiabetic subjects, it was found
that a single episode of acute hyperglycemia for 1 hour causes systemic oxidative stress
and lipid oxidation. However, neither acetylcholine (ACh)-mediated coronary endothelial
NO release nor the subsequent bioavailability, metabolism, or action of endotheliumderived NO within the coronary circulation was reduced. This may be due to the short
length of the experiment (58). For these studies, the researchers used AChor other
vasodilators to evaluate vascular dilatory function. Furthermore, they did not measure
blood NO and H202 changes in real time. Moreover, there is a lack of knowledge that
hyperglycemia induced eNOS uncoupling is due to reduced BH4/BH2 ratio or
insufficiency of L-arginine (17; 53). None of the above experiments utilized eNOS
substrates (eg. L-arginine), eNOS coupling cofactor (eg. BH4), or eNOS uncoupling
factor (eg. BH2) to evaluate blood NO and H202 in real-time in-vivo.
Our lab has established a novel method to measure blood NO and H20 2 from rat
femoral veins in real-time (16; 61; 77). Minni et al. found that acute hyperglycemia
induced higher H20 2 and lower NO levels in blood, which is consistent with acute
hyperglycemia-induced vascular dilatory dysfunction and systemic oxidative stress found
in other studies.
In order to further clarify the role of eNOS uncoupling on vascular endothelial

function under hyperglycemic conditions, we plan to monitor blood NO and H20 2 in real
time under three hours acute hyperglycemia, and with supplementation ofBH4, BH2, or
L-arginine to test the following hypotheses:
I . Acute hyperglycemia (200 mg/dL) will increase H20 2 and decrease NO release
in blood relative to saline control.
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2. BH4 (MW=314.20 g/mol, 6.5 mglkg) or L-arginine (MW=210.66 g/mol, 600
mg/kg) will attenuate acute hyperglycemia-induced blood NO/H202 change.
3. BH2 (MW=239.23 g/mol, 4 mg/kg) will exacerbate acute hyperglycemiainduced blood NO/H202 change.
This study aims to provide novel evidence regarding the contribution of eNOS
uncoupling to SO production and reduced NO bioavailability during acute
hyperglycemia. Furthetmore, this study will provide potential treatments to improve
vascular function and to prevent further tissue/organ damage under acute hyperglycemic
conditions.
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Methods
NO or H202 Microsensor Calibration
Prior to surgery, the NO or H202 microsensors (100 Jlm, World Precision
Instruments (WPI), Sarasota, FL) were calibrated using known concentrations of NO and
H202 solutions as per the manufacturer's recommendations. The selective membrane
covering the sensor dictates the specificity of the free radical microsensors. NO or H202
in the solution or biological fluid diffuses through the membrane and is oxidized at the
working electrode. At this point an electrical (oxidation/reduction) signal is generated
with amplitude propmtional to the free radical concentration of each specific sample.
The different sensors have a selective poise voltage important for obtaining reliable data.
A high perfmmance Faraday shield incorporated in the sensor is used to m inimize
environmental noise (88).
A standard curve was constructed based on electrical changes responding to
known concentrations of the free radical of interest. This enabled a conversion of the
electrical signal recorded during the experiment to a molar concentration ofNO or H202.
To retrieve a baseline, the NO and H202 microsensors were soaked in 10 mL copper
sulfate and 10 mL of PBS respectively. The microsensors were connected with cables to
the Apollo 4000 free radical analyzer (WPI, Sarasota, FL). A standard solution (i.e. 100
JlM) made from 100 mL of distilled water, 0.0022 g ofS-Nitroso-N-Acetyl-D,LPenicillamine (SNAP), and 0.002 g of ethylenedi aminetetraaceitic acid (EDTA) was used
to calibrate the NO microsensor. SNAP is a NO donor and has an efficiency of 60% to
convert into NO when using copper sulfate (Cu 2+). Once the baseline recording of the
NO microsensor became stable, known concentrations of SNAP (0-200 nM) were added
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to the copper sulfate to generate the cunent-NO concentration curve and detive the
calibration formula. To calibrate the H202 sensor, a standard (1 mM) H20 2 solution was
then added to 10 mL of PBS in a range of0-2 J..tM to generate a standard curve and derive
the corresponding calibration formula. The respective NO and H202 sensor calibration
formula was used to convert the experimentally measured electrical change to a blood
NO (nM) and H202 (J..tM) concentration change.

Animal Preparation

The Institutional Animal Care and Use Committee of Philadelphia College of
Osteopathic Medicine approved all animal protocols followed in this study.
Once calibration of the free radical sensors was complete, male Sprague-Dawley
rats (Charles's River: Charles's River, Kinston, NC) ranging from 0.275-0.325 kg were
anesthetized with 60 mg/kg of 50 mg/ml pentobarbital sodium injections and anticoagulant 1000 unit heparin via intraperitoneal (i.p.) injections. A maintenance dose of
30 mg/kg pentobarbital sodium (i.p.) was administered as needed to maintain anesthesia
throughout the procedure.
The animal preparation is illustrated figures 3 and 4. Initially, the jugular vein
was catheterized (24 gauge catheter) superiorly to inferiorly for introducing the following
control or expelimental solutions after establishing a baseline. The 20% D-glucose
solution was freshly made by dissolving 3g ofD-glucose into 15 ml of0.9% sodium
chloride in order to introduce hyperglycemia at 200 mg/dL, for 3 hours after a loading
dose of20% D-glucose 0.25 ml/min for 4 minutes. BH4, BH2, and L-arginine were added
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to 20% glucose to reach approximately 250

~tM,

200

~M,

and 27.6 mM in blood,

respectively. Saline infusion served as the control.

Figure 3. The cathetelization of the jugular vein as anow indicates.

Both femoral veins were exposed and catheterized in order to place a calibrated NO
microsensor in one femoral vein and a calibrated H202 microsensor in another at random
(see figure 4). These microsensors were connected to an Apollo 4000 monitor to measure
blood NO and Hz02 levels in real-time. Baseline readings ofblood NO and Hz02 were
established after about an hour stabilization period. Then the saline or other treatment
solutions (i.e. 20% 0-glucose, 20% D-glucose with 6.5 mg/kg BH-1, 20% D-glucose with
4 mg/kg BH2, or 20% D-glucose with 600 mglkg L-arginine (see figure 3) were
administered at a rate of0.25 mL/min for the first four minutes tor a loading dose.
Subsequently, the infusion speed was adjusted at rates fi·om a range of0.014 mL/min to
0.025 mL/min to maintain 200 mgldL hyperglycemia level throughout the remainder of
the experiment for any test solutions containing 20% D-glucose. Infi.1slon speed was
maintained at 0.025 mL/min for the saline control group. Blood NO and H202 were
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recorded continuously at 20 min intervals for a total of 180 min after intravenous infusion
of different treatment/control solutions. In every group, blood glucose was recorded from
tail vein samples at the beginning and every 20 min through the experiment via an
Ascensia Contour blood glucose meter. Respiratory rate was monitored as an indicator of
the level of anesthesia throughout the procedures.

Figure 4. NO and H202 microsensors in the femoral veins.

After the experiment was completed, the animal was euthanized while maintaining
anesthesia by opening the thoracic cavity through the diapmagm and transecting the
aortic artery and vena cava. These were immediately removed along with the abdominal
mesentery and one kidney and placed in 4% parafonnaldehyde for future histochemistry
analysis. The heart, thoracic aorta, and remaining kidney were harvested and frozen for
fut-ure western blot analysis of adhesion molecules and blood plasma was collected for
future analysis of serum cytokines and nitTite levels.
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The current changes in NO or H202 release during the experiment (in picoamps) were
expressed as change relative to the baseline. Subsequently, the blood NO and H202
recording in picoamp values were converted to the concentration of NO (nM) or H20 2
(J.LM) according to the corTesponding calibration fonnula for the free radical microsensors
previously generated. In order to further clarify the influence of 20% D-glucose, 20% Dglucose with BH4, 20% 0-glucose with BH2, and 20% D-glucose with L-arginine on
blood NO and H202, data was also expressed as relative NO or H202 change under these
conditions by subtracting the NO or H202 values for the saline control group at each time
point.

Experimental Groups

There were a total of 5 experimental groups in this study:
1.) Saline control group (n=6 for NO and n=7 for H20 2): The animals had the same

surgery and were monitored for blood NO and H202 concentration changes when saline
was intravenously infused for 3 hours following a one hour baseline period. This group
was designed to show that the animal can undergo the surgery and maintain stable
conditions throughout the whole experiment period. Moreover, the level of blood NO
and H202 in this group reflected the real-time vascular endothelial function and served as
control to evaluate the change under hyperglycemic conditions.
2.) Hyperglycemic group (n=6 for NO and n=6 for H202): The animal was

intravenously infused with 20% D-glucose in order to maintain hyperglycemic conditions
at 200 mg/dl in the blood for 3 hours. This group was designed to evaluate the real-time
blood NO and H202 changes during hyperglycemic conditions.
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3.) Hyperglycemia+ BH4 [MW=314.20 g/mol, 6.5 mg/kg](n=6 for NO and n=6 for
H202): The animal was intravenously infused with 20% D-glucose with 6.5 mglkg BH4 in
order to maintain hyperglycemic condition at 200 mg/dl and approximately 250 J..LM BH4
in blood for 3 hours. This group was designed to evaluate if addition of eNOS coupling
cofactor, BH4, can attenuate higher blood H202 and enhance blood NO levels under
hyperglycemic conditions. The dose of BH4 was chosen based on the anti-oxidant effects
observed in femoral ischemia/reperfusion model (16).
4.) Hyperglycemia+ BH2 [MW=239.23 g/mol, 4 mg/kg](n=6 for NO and n=7 for

H202): The animal was intravenously infused with 20% D-glucose with 4 mg/kg BH2 in
order to maintain hyperglycemic conditions at 200 mg/dl and approximately 200 J..LM BH2
in blood for 3 hours. This group was designed to evaluate the real-time blood NO and
H202 change during hyperglycemic conditions with BH2, an oxidized form ofBH4 that
serves as a cofactor for uncoupled eNOS. The addition ofBH2 was expected to
exacerbate hyperglycemia induced blood H20 2/NO changes.
5.) Hyperglycemia+ L-arginine [MW=210.66 g/mol, 600 mg/kg](n=5 for NO and n=6

for H202): The animal was intravenously infused with 20% D-glucose with 600 mg/kg Larginine in order to maintain hyperglycemic conditions at 200 mg/dl and approximately
27.6 mM L-arginine in blood for 3 hours. This group was designed to evaluate if eNOS
uncoupling caused by hyperglycemia may be due to the insufficient supply of the eNOS
substrate, L-arginine. The addition of L-arginine was expected to attenuate
hyperglycemia induced blood H20 2/NO changes.

Statistics
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All the data in text and figures are represented as a mean ± the standard error of the mean
(SEM). When comparing more than two groups, the data was analyzed by an ANOVA
followed by a post hoc Student Newman Keuls test for paitwise comparison of
subgroups, when the ANOVA test was significant. Probability values of <0.05 were
considered to be a statistically significant result.
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Results

The animals exhibited normal vital signs for all groups throughout the
experimental period. In the hyperglycemic groups, some of the rats statied to minate
from the 60 minute mark and maintained the urination throughout the rest of the
expetimental time.

Blood glucose levels in experimental groups

The blood glucose levels in every experimental group are shown in figure 5. The
baseline level of blood glucose concentration ranged from 73-81 mg/dL and there was no
significant difference among the groups. Infusion of saline for 180 min slightly increased
blood glucose to 97±3 mg/dL (n=2) at the end of the experiment, which is the nonhyperglycemic condition.
Blood glucose levels were all around, but slightly higher than, the 200 mg/dL
target level for all of the 20% glucose infusion groups. This indicates that the infusion of
the 20% D-glucose groups was able to reach 200 mg/dL glucose levels. Meanwhile, the
drugs (i.e. BH4, BH2, and L-arginine) have no impact on blood glucose. Blood glucose
was increased to 184±34 mg/dL after 20 min infusion of 20% D-glucose. Thereafter, the
blood glucose was maintained around 200 mg/dL (n=6), showing: 209±39 mg/dL at 40
min, 193±49 mg/dL at 60 min, 20 1±55 mg/dL at 80 min, 226± 17 mg/dL at 100 min,
242±31 mg/dL at 120 min, 232±38 mg/dL at 140 min, 226±44 mg/dL at 160 min, and
233±12 mg/dL at 180 min ofthe continuous infusion. In the 20% D-glucose infusion
group with BH4, blood glucose increased to 236±26 mg/dL (n=8) after 20 min infusion.
Thereafter, the blood glucose was kept around 200 mg/dL with continuous infusion.
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Blood glucose was 224±17 mg/dL at 40 min, 247± 17 mg/dL at 60 min, 238±16 mg/dL at
80 min, 255±19 mg/dL at 100 min, 252±22 mg/dL at 120 min, 261±8 mg/dL at 140 min,
240±12 mg/dL at 160 min, and 245±10 mg/dL at 180 min of the continuous infusion. In
the 20% D-glucose infusion group with BH2, blood glucose was raised to I 78± 12 mg/dL
(n=8) after 20 min infusion. Thereafter, the blood glucose was kept around 200 mg/dL
with continuous infusion. Blood glucose was 184±23 mgldL at 40 min, 256±25 mg/dL at
60 min, 252±20 mg/dL at 80 min, 236±18 mg/dL at 100 min, 239±21 mg/dL at 120 min,
226± 18 mg/dL at I 40 min, 241± 14 mg/dL at 160 min, and 253± I 2 mg/dL at 180 min of
the continuous infusion. Lastly, in the 20% D-glucose infusion group with L-arginine,
blood glucose was raised to 204± 11 mg/dL {n= ll) after 20 min infusion. Thereafter, the
blood glucose was kept around 200 mg/dL with continuous infusion. Blood glucose was
225±28 mg/dL at 40 min, 239±22 mg/dL at 60 min, 251 ±24 mg/dL at 80 min, 205±10
mg/dL at IOO min, 242±24 mg/dL at 120 min, 250±20 mg/dL at 140 min, 238±14 mg/dL
at 160 min, and 244±20 mg/dL at 180 min of the continuous infusion.

27
350~r=========================================================1--l
..... Saline Control (n:2)
..,._ 20%0-glucose + BH4 (n•6)
-+- 20"• 0-glucose + L-arginine (n:6)

..._ 2or. O.glucose (n:6)

20'• 0-glucose + BH2 (n•7)

250

ig
d)
(I)

0

u

e

I 150

50~~-----,r-----r-----~----~----,------r-----.-----.-----.--~

100

140
160
180
baseline
20
40
60
80
120
' - - - - - - - - - Intravenous Infusion (min.) - -- - - - - - - - - - - -- - - - - - - -- '

Figure 5: The comparison of blood glucose levels among saline and 20% D-glucose
hyperglycemia infusion groups with or without the drugs throughout 3 hours experimental time.
The saline group maintaiued the normal blood glucose levels. By contrast, any group containing
20% glucose increased blood glucose to about 200 mg/dL throughout the 180 minute infusion.

Blood NO levels in experimenbtl groups
Figure 6 illustrates the blood NO levels relative to baseline among the different
experimental groups. In the saline group, blood NO levels remained stable and only
slightly decreased by 25.9±12.86 nM (n=6) at 180 minutes. In the 200 mg/dL
hyperglycemic group (n=6), blood NO dropped to a significantly lower level at 100
minutes (p<0.05), and continuously decreased throughout the rest of infusion (all p<O.Ol )
in compatison to saline group (figure 6). Blood NO levels decreased by 115.73±9.98 nM
(n=6) at 180 minutes in 200 mg/dL hyperglycemia group. Furthermore, the blood NO in
the 20% Glucose + BH2 f,•roup (n=-=6) decreased immediately after infusion and remained
significantly lower at the 40 minute (p<O.Ol ), 80 minute (p<0.05), and from the 100 to

28
180 minute marks {p<O.O 1) compared to the saline group (figure 6). Blood NO levels
decreased by 175.65±27.36 nM (n=6) at 180 minutes in 200 mgldL glucose with BH2
group. Moreover, we found that BH2 exacerbated the hyperglycemia- induced decrease
in NO levels. A significant NO decrease in 20% Glucose +BI-h group was found at the 40
minute mark, and from the 100 through 180 minute interval compared to 200 mgldL
hyperglycemia (p<0.05, figure 6).
By contrast, the 200 mg/dL hyperglycemia with coupled eNOS cofactor, BH4. or
the coupled eNOS substrate, L-arginine, showed no significant difference from the saline
control. Furthermore, BH4 or L-arginine treatments also significantly increased blood NO
levels compared to the hyperglycemia group. At 120 minutes, NO levels in the 200
mg/dL hyperglycemia with BH4 only decreased by 35.8± 10.01 nM (n=6). Similarly, NO
levels in the 200 mgldL hyperglycemia with L-arginine only decreased by 23.33±9. 12nM
(n=5). This indicated that both the BH4 and L-arginine effectively attenuated the
hyperglycemia induced reduction in NO levels (figure 6).
Blood NO levels also were expressed as relative change to the saline group and
illustrated in figure 7. The saline control was set as zero at each time point (figure 7).
Similarly, as illustrated in figure 6, hyperglycemia significantly decreased blood NO
levels. Moreover, the addition ofBH2 temporally caused significantly decreased blood
NO levels at the 40 and 100 through 180 minute time intervals compared to the
hyperglycemia group (figure 7). However, the addition ofBH4 or L-arginine significantly
increased blood NO levels compared to the hyperglycemia group (figure 7). Both traces
were getting close to the saline group.
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Blood H202 levels in experimental groups

Figure 8 illustrates the blood H202 levels relative to baseline among the different
experimental groups. In the saline group, blood H202 levels decreased continuously by
4.59±0.33 )..I.M (n=7) at 180 min. In the 200 mg/dL hyperglycemic group (n=6), blood
H20 2 remained at a significantly higher level from 40 minutes (p<0.05) to 180 minutes
(p<O.Ol at 60, 80, 100, 120, 140, 160, 180 min.) ofinfusion compared to the saline group
(figure 8). At 180 minutes, blood H20 2 in the hyperglycemia group decreased only by
0.8±0.43 )..I.M compared to baseline, which is significantly higher compared to the saline
control (p<O.Ol ).
Furthetmore, the blood H202 in the 200 mgldL hyperglycemic with BH2 group
(n=7) also remained significantly higher from the 20 minute to 180 minute intervals
(p<O.O l ) compared to the saline group, but similar to the hyperglycemic group (figure 8).
At 180 minutes, blood H202 in the BH2 treated hyperglycemia group decreased only by
0.94±0.27 )..I.M compared to baseline, which was significantly higher compared to saline
control (p<O.Ol). Additionally, we found that 200 mg/dL hyperglycemia with BH2
tempormily exacerbated hyperglycemia- induced increase in H202 levels only from 40
minutes to 60 minutes compared to 200 mg/dL hyperglycemia (p<0.05, figure 8).
By contrast, the blood H202 levels in 200 mg/dL hyperglycemic with coupled
eNOS cofactor BH4 only showed a significant difference from the saline control at the 20
minute interval (p<O.Ol). Blood H20 2 concentration continuously dropped and decreased
by 3 .89±0.53)..1.M (n=6) after 180 minutes of infusion. Similarly, the blood H202 levels in
200 mgldL hyperglycemia with L-arginine decreased by 3.3 1±0.043)..1.M (n=6) after 180
minutes of infusion, which was not significantly different from the saline control or 20%
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glucose + BH4 groups. Moreover, BH4 and L-arginine treatments significantly reduced
blood HzOz levels compared to those in the hyperglycemia groups. This indicates that
both the BH4 and L-arginine effectively attenuated the hyperglycemia-induced increase in

HzOz levels (figure 8).
In figure 9 the graph was remade to show the time course of HzOz change during
hyperglycemia with or without the drugs relative to saline. This is a more comprehensive
illustration ofthe relative increase in HzOz induced by the hyperglycemic condition
compared to the saline group. The saline control was set as zero at each point and the
differences of blood HzOz levels between hyperglycemia and saline were plotted on the
graph (figure 9). Similarly as illustrated in figure 8, hyperglycemia significantly
increased blood HzOz levels. Moreover, the addition ofBH2 temporally significantly
increased blood HzOz levels at the 40 and 60 minutes compared to the hyperglycemia
group (200 mg/dl). However, the addition of BH4 or L-arginine significantly reduced
blood HzOz levels compared to the hyperglycemia-group.
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Discussion
Summary of Results
The major findings of this study were: first, intravenous infusion of 20% of Dglucose induced 200 mg/dL hyperglycemia and the degree of the hyperglycemic
condition was maintained for 180 minutes with continuous infusion. Moreover, addition
ofBH4, BHz, or L-arginine had no impact on blood glucose levels. Secondly, blood NO
levels were significantly reduced during hyperglycemic conditions sta1ting at l 00 min
through the rest ofthe hyperglycemic period as compared to the saline control group.
Thirdly, under hyperglycemic conditions, blood Hz0 2 levels were significantly higher as
compared to the saline control group. The fourth major finding was that 20% D-glucose
with BH2 significantly exacerbated blood NO reduction and higher blood Hz02 levels
compared to the 20% D-glucose infusion hyperglycemic conditions. The next finding, by
contrast, showed that the addition ofBH4 with hyperglycemia significantly improved
blood NO levels and reduced blood H202 levels under hyperglycemia, similar to the
levels found in the saline control. Finally, L-arginine with hyperglycemia significantly
improved blood NO levels and reduced blood H202 levels under hyperglycemia, similar
to the levels found in the saline control.

Acute Hyperg lycemic rat model
We have established an acute hyperglycemia induced vascular endothelial
dysfunction rat model by measuring blood NO and H202levels in real-time. The
hyperglycemic rat model was based on the rat model used by Saha et al. as well as a
previous study performed in our laboratory by Minni (61 ). They showed that an initial
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bolus injection of20% D-glucose produced a maximum acute increase in blood glucose
level (about 200 mg/dL). This increase was sustained when the rats received a constant
glucose infusion throughout the experimental period (69). Similarly, in our
hyperglycemic rats the bolus infusion of 1 ml D-glucose solution within a 4 minute time
period was used for a loading dose, following which the infusion rate was reduced tenfold to sustain the target blood glucose concentration during the 180 minute experiment
infusion time. We found that this infusion method can reach 200 mgldL hyperglycemic
conditions around 20-60 min and could stay reasonably constant throughout the rest of
experiment, if manipulated properly. All of the animals in all ofthe groups maintained
relatively stable respiratory rates throughout the study conditions. Under hyperglycemic
conditions with or without drugs, rats urinated at 60 minutes to the end of the infusion,
which is consistent with our previous findings by Minni et al. The urination was most
likely caused by hyperosmolarity in the hyperglycemic rats (61).

Mechanisms related to hyperglycemia-induced blood NO and H202 changes

Overview
Oxidative sh·ess is a key factor in hyperglycemia-induced vascular endothelial
dysfunction. The present study, in which blood NO and H202 levels were measured,
confitmed Minni et al. ' s finding that oxidative stress exists during acute hyperglycemia.
It was previously suggested that the sources of oxidative stress during hyperglycemia

include: uncoupled eNOS, NADPH oxidase, and the mitochondrial respiratory chain (9;
26; 27). It was additionally suggested that all three sources can produce excess SO in a
hyperglycemic state. As a result, SO will directly quench NO to form ONoo· and reduce

35
NO bioavailability. Superoxide dismutase (SOD) can also further convert SO to H20 2.
Both ONoo· and H202 can subsequently lead to eNOS uncoupling. Uncoupled eNOS
produces SO instead of NO to further induce oxidative stress. Hence, the more SO being
produced can in turn uncouple more eNOS. This interaction between NO and oxidative
stress may well facilitate a vicious and detrimental cycle (see figure 10) which can
promote vascular endotheli al dysfunction, persistent inflammation, and even tissue or
organ damage.

Hyperglycemia

~
NADPH oxidase, Xanthine oxidase,
Mitochondria respiratory chain

Catalytically
achve •ron
Coupled

e NOS
uncoupled

OxfdlzedL - - - - - - BH4

Figure l 0. A representation of the vicious cycle oxidative stress during hyperglycemia
conditions. An overview of the method of how the production of free radicals from
hyperglycemia can propagate a continuous production of more free radicals (Modified from
Wood eta!., 2006).

36
Levels ofBlood NO under Control and Acute Hyperglycemic Conditions
Postprandial hyperglycemia has been highlighted in healthy non-diabetic subjects
as it has been shown to induce vascular endothelial dysfunction (13). Kawano et al.
found that the post-prandial hyperglycemia after an oral glucose loading (i.e. OGTI)
rapidly suppresses endothelium-dependent vasodilation, possibly by an increased
production of oxygen-derived free radicals, in a group of healthy subjects ( 40). Title et al.
found that an OGTI in 10 healthy individuals led to an acute transient attenuation of the
endothelium-dependent flow-mediated dilation of the brachial artery (FMD). The method
ofFMD has been shown to be dependent on the release of endothelium derived NO.
Consequently, when there is a decrease in the FMD, it would imply a loss of NO
bioavailability and vascular endothelial dysfunction (79).
In the present study, acute hyperglycemia induced vascular endothelial

dysfunction was demonstrated by measuring blood NO bioavailability in real time. Blood
NO levels in the saline control group were relatively stable and dropped only slightly
(approximately 26 nM relative to the baseline) within the 180 minute infusion period.
The stability of blood NO in anesthetized rats had been consistently observed in the other
two anesthetized animal models in our laboratory' s femoral ischemia/reperfusion injury,
extracorporeal shock wave lithotripsy (ESWL) animal models (16). In contrast to saline
control, 200 mg/dL hyperglycemia showed to significantly decrease blood NO relative to
the baseline, and the blood NO levels continuously reduced throughout the rest of
hyperglycemia (200 mg/dL). At 180 min, blood NO is reduced by 115.73±9.98 nM
(n=6). These findings are consistent with the clinical acute hyperglycemia induced
decrease in FMD. Our data support that real time measurements of blood NO levels is a
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clear indication that acute hyperglycemia significantly reduces endothelial-derived NO
bioavailability and the effects can be sustained throughout the hyperglycemia.

Levels ofH202 under Control and Acute Hyperglycemic Conditions
Oxidative stress is a major causal factor that has been linked to hyperglycemic
induced vascular endothelial dysfunction. In a study by Marfella et al., nitrotyrosine, a
marker for oxidative stress, rose significantly in 20 healthy subjects under the effects of
acute hyperglycemic conditions (55). Nitrotyrosine has been found to be a suitable
marker of ONoo- and nitrosative stress generation, and increased nitrotyrosine plasma
levels have been found in the plasma of diabetics ( 15). This present study utilizes blood

I-hOz levels to indicate SO production under acute hyperglycemia. SO has a very shmt
half-life of seconds and it can be quickly converted into Hz0 2 by SOD. Increased blood
H202 is conelated to oxidative stress under different pathophysiological conditions, such

as ischemia-reperfusion, ESWL, and acute hyperglycemia (16; 61). In this study, H202
levels dropped approximately 4.50 ± 0.33 j..t.M within 180 minutes in the saline group.
This observation was presumably attributed to a decrease in body temperature when the
anesthetized rat was positioned on a thermostatic platform for over 240 minutes (61 ).
This HzOz blood level decrease was also observed in our laboratory femoral
ischemia/reperfusion injury and ESWL rat models (16). The 200 mg/dL hyperglycemia
group had a significantly higher blood Hz02 level compared to saline control, dropping
0.8 ±0.43 j..t.M from baseline within 180 minutes. The significant increase in HzOz levels
started at the beginning of the intravenous infusion of20% D-glucose (i.e. 40 min).
Moreover, blood H202 levels also continuously increased when hyperglycemia infusion
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was maintained , which indicates that hyperglycemia may directly induce oxidative stress
via amplification mechanisms (see Fig. 10). We also proved that there is an inverse
relationship between blood NO and oxidative stress (i.e. H20 2 levels) in blood under
hyperglycemic conditions.

Coupled/Uncoup led eNOS
Nmmally eNOS maintains a coupled status by linking electron transfer with
oxidation of L-arginine to generate L-citruline and NO in the presence of an essential cofactor BH4 (72) . BH4 has been shown to stabilize eNOS dimer structure which has a
catalytic function (26). However, under oxidative stress, BH4 can be oxidized to BH2
which can then occupy the eNOS oxygenase domain and block electron transfer to Larginine. At this point, eNOS becomes uncoupled and starts to generate SO instead ofNO
(see figure I) (83). Fonseca et al. found that H202 can induce a dimer collapse in the
eNOS as well as a loss of a zinc from the enzyme, and both cause eNOS uncoupling (26).
Additionally, the overproduced SO during hyperglycemia can bind to NO very quickly to
form ONoo-. ONoo- can oxidize BH4 to BH2 resulting in a decreased BH4 to BH2 ratio.
Since eNOS has an equal affinity for binding to BH4 and BH2 it becomes uncoupled and
produces SO instead of NO (17). This may be one way in which oxidative stress during
hyperglycemia can propagate a vicious cycle which increases SO production and directly
reduces NO bioavailability by fotming ONoo-. Subsequently, ONoo- and H20 2 further
cause eNOS uncoupling to produce SO instead ofNO. Thereafter, more SO is generated,
while less NO is produced. This cycle can keep repeating and the ROS produced can
cause serious damage to vascular endothelial function. In our present study, 200 mg/dL
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with BH2 exhibited significant blood NO reduction and higher blood H202 levels
compared to the saline control conditions. Moreover, 200 mg/dL glucose with BH2
exacerbated a significant blood NO reduction and higher blood H20 2 levels compared to
the 20% D-glucose infusion induced hyperglycemic conditions. This indicates that
adding BH2 may further lower the BH4 to BH2 ratio, thus facilitating more eNOS
uncoupling than hyperglycemia alone.
By contrast, 200 mg/dL glucose with BH4 showed the opposite effects on blood
NO levels compared to that in 200 mg/dL + BH2 groups: an increase in NO that was
similar to the saline control levels. Furthermore, the addition of BH4 also showed a
significant decrease in H20 2 compared to the blood H20 2 levels during hyperglycemia.
Moreover, the H20 2 levels in BH4 treated hyperglycemia also were similar to the saline
control levels. Therefore, the addition of BH4 effectively attenuated hyperglycemia
induced vascular dysfunction and oxidative stress. These results are consistent with
clinical studies that suggest that adding BH4 can reverse OGTT-induced vascular dilatory
dysfunction in normal subjects (81 ). A possible explanation for the effects of BH4 is that
the addition ofBH4 can increase the BH4 to BH2 ratio, which effectively leads to the
promotion of eNOS coupling and stabilization of the dimer structure of eNOS in
hyperglycemia. Therefore, uncoupled eNOS following oxidative stress induced by
hyperglycemia seems to be a major factor in the exacerbation of blood NO and H20 2
changes and vascular endothelial dysfunction. By contrast, the promotion of coupling
eNOS by adding BH4 may well be a way to overcome these negative effects of acute
hyperglycemia on the vasculature.
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This present study established the roles of eNOS coupling and uncoupling on
acute hyperglycemia-induced vascular dysfunction and oxidative stress by measuring
blood NO and H202 levels in real-time. The acute hyperglycemia groups had
significantly decreased blood NO levels and significantly higher blood H202 levels. The

H202 increase occmTed directly after induction of the acute hyperglycemia, whereas the
reduction of endothelial-derived NO bioavailability took place from the 100 minute point
of acute hyperglycemia onward. This indicates that oxidative stress is a predecessor of
vascular endothelial dysfunction under the acute hyperglycemic condition, and suggests
that acute hyperglycemia for a duration of 180 mins increased oxidative stress and
reduced endothelial-derived NO bioavailability. We also established that adding BH2 and
inducing more eNOS uncoupling can further decrease NO bioavailability and increase
blood H202. Furthermore, BH4 may attenuate the levels ofblood NO and H20 2 to levels
similar to those found in saline control samples. These results indicate that most acute
hyperglycemic changes can be attenuated by promoting eNOS coupling.

L-arginine

L-arginine serves as the substrate in the process of coupled eNOS for producing NO and
has been shown to stabilize the eNOS dimer stmcture, which has catalytic function, in a
mechanism similar to BH4 (26). This is an important factor as insufficient L-arginine can
simulate the enzymatically uncoupled molecular oxygen to produce SO, resulting in SO
production instead of NO. Mah et at. has shown that plasmaL-arginine decreases in a
postprandial period of acute hyperglycemia (53). Endothelial cells express arginases, of
which arginase II is the predominant isoform, whose function is to metabolize L-arginine
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into L-omithine and urea (24). Mah et al. proposes that an upregulation of arginase may
be responsible for the decrease in arginine (53). It has been shown that there is a greater
upregulation of arginase activity in diabetic individuals compared to healthy controls.
The study by Mah et al. also gives us novel evidence that acute hyperglycemia in healthy
young participants increases the asymmetric dimethyl-L-arginine (ADMA):arginine ratio,
an index of reduced NO biosysnthesi s. ADMA is an endogenously produced competitive
inhibitor of eNOS, which competes locally with L-arginine. Oxidative stress caused by
the acute hyperglycemia may also inhibit dimethylarginine dimethylaminohydrolase
(DDAH)-mediated ADMA degradation, which results in a greater intercellular ADMA
concentration (53). Mah et al. concludes that the increase in ADMA:arginine during
acute hyperglycemia may cause impairments in the eNOS-mediated biosysnthesis of NO
and vascular function. L-arginine may also have non-substrate effects, such as a potential
direct radical scavenging effect based on the guanidine nitrogen group (27). In this
current study, 200 mg/dL with L-arginine produced effects similar to those produced by
BH4. The addition of L-arginine led to an increase in NO levels compared to NO levels
during hyperglycemia, which were similar to the saline control levels. In contrast,
addition of L-arginine showed a significant decrease in H202 compared to H20 2 levels
during the hyperglycemia which is also similar to the saline control levels. Therefore the
L-arginine also effectively attenuated the hyperglycemia induced vascular dysfunction.
These results suggest that an increase in the substrate (i.e. L-arginine) of coupled eNOS
may maintain coupled eNOS function, thus continuously producing NO. We have also
noticed that L-arginine had an initially quicker protective function compared to BH4 from
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the oxidative stress cause by hyperglycemia, which may be attributed to antioxidant
properties of L-arginine.

Other Possible Sources of ROS Production
NADPH Oxidase

NADPH oxidase is a multi-subunit enzyme that catalyzes SO production by the
reduction of molecular oxygen by using NADPH as an electron donor. In addition to
neutrophils, where it was originally discovered, NADPH oxidase is also present in
endothelial cells, vascular smooth muscle cells, fibroblasts, and some other cells (87).
The physiological nonphagocytic NADPH oxidase derived SO is usually in low
concentrations and has been implicated in the regulation of migration, activation,
proliferation, vascular tone, and vascular cell growth (1 0; 80). However, ifNADPH
oxidase is upregulated the increased quantity of SO produced can result in oxidative
stress. Many studies have indicated that hyperglycemia can activate the enzyme PKC in
vascular endothelial cells. Hyperglycemia may stimulate SO production through a PKCdependant activation ofNADPH oxidase in vascular endothelial cells (38). Inogouchi et
al. found that exposure of aortic endothelial cells to a hyperglycemic level of 400 mg/dL
for 72 hrs led to a significant increase in free radical production compared with cells
exposed only to a nonnal glucose level of 100 mg/dL (38). Inogouchi also found that the
increase in free radical production was attenuated with the use of a NADPH oxidase
inhibitor, diphenylene iodonium (38). Inoguchi 's results suggest that hyperglycemia may
induce ROS production by vascular NADPH oxidase following PKC activation. In
addition, it has been found that SO production is significantly increased in streptozotocin-
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induced diabetic rats two weeks after the onset of diabetes. Santa et al. found that a
NADPH oxidase inhibitor or PKC inhibitor can significantly attenuate this oxidative
stress in these streptozotocin-induced diabetic rats (74). Moreover, the transition of
coupled eNOS to uncoupled eNOS demands oxidative stress. Overproduction of SO via
activated NADPH oxidase may be a major source of oxidative stress to further cause
eNOS uncoupling. All of these findings makes the investigation of a NADPH oxidase
inhibitor to attenuate the blood H202 increase/NO decrease in our acute hyperglycemia
model an exciting field for future studies.

Mitochondrial SO production
Human mitochondria produce the majority of the body's required adenosine
triphosphate through the process of oxidative phosphorylation (21 ). The system of
oxidative phosphorylation includes five large multienzyme complexes called electron
transfer chain (ETC) complex I-IV, and the ATP synthase complex V (32). Under
normal physiological circumstances, in most tissues, this system is an important source of
ROS (21 ). Meanwhile, SOD inside mitochondria removes SO to protect the
mitochondria from oxidative injury (54). During hyperglycemia, it has been hypothesized
that tricarboxylic acid (TCA) cycle electron donors (NADH and F ADH2) become
increased, which in turn increases the mitochondrial membrane potential. Once
mitochondrial membrane potential reaches a critical point, electron transport at complex
III is inhibited, further promoting the half-life of free-radical intermediates of co-enzyme
Q, which lead to the reduction of molecular oxygen to SO (9). Srinivasan et al. found
that chronic exposure of human aortic endothelial cells to elevated glucose (25 mM)
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reduced total nitrite levels by 46%, eNOS mRNA by 46%, and eNOS protein by 65%.
This effect was attenuated by the specific inhibition ofROS production through the
mitochondrial electron transport chain (ETC) (75). These findings demonstrate that
mitochondrial derived SO are another possible source of reducing NO bioavailability
under hyperglycemic conditions. This mechanism mediating eNOS uncoupling should be
further evaluated under acute hyperglycemia in vivo, as well by measuring blood NO and
H202.

D-glucose scavenging of NO
Glucose alone, in vitro, has been shown to promote NO loss. Brodsky et al. found
that glucose has a direct scavenging effect by quenching NO (8). Brodsky et al. provided
experimental evidence suggesting that when blood glucose was elevated to 270 mg/dL in
healthy human subjects, there was a significant reduction in NO-mediated vasoactivity
which lead to an increase in systolic and diastolic blood pressure and a decrease in blood
flow to the leg (8). This may well serve as another possible mechanism to explain the
drop in blood NO levels under acute hyperglycemic conditions.
Limitations
Most of the information about hyperglycemia's effects on vascular endothelial
dysfunction has been detived from investigations that utilized a diabetic model. The acute
hyperglycemia employed in the study reported here was induced in a normal, healthy rat
model with nonnal insulin secretion that responded to a blood glucose change. Insulin
has been shown to have vasoactive properties that can cause less SO and more NO
production. However, Williams et al. , showed that the effects of acute hyperglycemia on

45

endothelium-dependent vasodilation were comparable after using octreotide to inhibit
pancreatic secretion of insulin, suggesting that hyperglycemia is the likely offender (86).
Moreover, since there was a continuous infusion ofD-glucose in the present study, the
excessive amount of glucose overrode the effects of insulin to maintain the acute
hyperglycemic conditions. Therefore, the blood NO and H202 level changes seen in this
study were indicative of the negative effects of acute hyperglycemia on vascular function.

Future Studies
Upon completion ofthis study, samples of blood, heatt, aorta, and kidney were
collected for future analysis. Plasma will be used to conduct a fluorescence Griess Assay
to measure the blood nitrite levels to confirm the NO data. Furthermore, blood
malondialdehyde concentration could be measured to reflect systemic lipid oxidation in
order to confirm systemic oxidative stress induced by the acute hyperglycemic
conditions. Plasma BH4 and BH2 ratios could also be measured by high-performance
liquid chromatography (HPLC) to determine if there was legitimate eNOS coupling or
uncoupling among different experimental conditions. Another way to look at the eNOS
coupled vs uncoupled ratio would be to do a western blot analysis by measuring eNOS
dimer and monomer levels. ADMA and L-arginine also could be measured to understand
the importance of acute hyperglycemia on the ADMA:arginine ratio and to compare with
Mah's studies.
Furthermore, this is a study to measure blood NO and H202 changes in real-time
as a means to establish the acute hyperglycemic effects on vascular endothelial function
and oxidative stress. We found that acute hyperglycemia groups had a significant drop in
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blood NO levels and a significantly higher blood H202 level in comparison to the saline
control group. We also established that BH4 and L-arginine attenuated this blood NO and
H202 change under hyperglycemia whilst BH2 exacerbated it. Our data suggests that
eNOS coupling and uncoupling status is a major contributor to vascular endothelial
notmal and abnormal function. Moreover, NADPH oxidase and mitochondrial SO
production may be the major sources causing eNOS uncoupling under hyperglycemic
conditions. Therefore, further studies are needed to explore these related mechanisms by
using NADPH oxidase inhibitor (diphenylene iodonium, gp91ds-tat) or mitochondrialtargeted antioxidant (i.e. SS-31 or mitoquinone).

Conclusion

In summary, we found that acute hyperglycemia significantly induces oxidative
stress and vascular endothelial dysfunction. Moreover, the addition of BH2, which
facilitates eNOS uncoupling, exacerbates both changes under hyperglycemia. By
contrast, the addition of L-arginine, or BH4, which promote eNOS coupling, significantly
improves vascular endothelial function and reduces oxidative stress. Therefore, this study
provides novel evidence for the role of eNOS uncoupling in vascular endothelial
dysfunction and oxidative stress under acute hyperglycemia.
Clinical Relevance

As acknowledged in the introduction, hyperglycemia is linked to vascular
endothelial dysfunction by increasing oxidative stress. Vascular endothelial dysfunction
due to this prolonged oxidative stress has been associated with cardiovascular disease and
atherosclerosis. The purpose of this study was to establish the role of eNOS in vascular
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endothelial dysfunction in an acute hyperglycemic model to help prevent vascular
dysfunction and other circulatory complications in non-diabetic or prediabetic
individuals. Hyperglycemia has been linked to the progression of diabetic nephropathy
which was demonstrated when Piwkowska et al. showed that hyperglycemia produced
reactive oxygen species causing morphological and functional changes in mouse
podocytes (66). Maintaining normal glucose levels during surgery has been shown to be
important in avoiding complications such as blood clots and stroke as well. Psychological
stress is another factor that can cause hyperglycemia, so eliminating chronic
psychological stress will be significant in avoiding future vascular complications also.
This present study should also bring more attention to the hazards of postprandial
hyperglycemia. It has been well established that an excess of dietary saturated fat and
dietary sodium consumption is directly associated with cardiovascular diseases. To live a
healthy life and prevent some of these problems, individuals have learned to reduce their
intake of dietary fat and sodium. However, commonly consumed foods that raise your
blood glucose like soda, fruit juice, and candy are not commonly seen through the eyes of
the public as hazardous to their cardiovascular health. A 20 oz bottle of one of the leading
grape sodas contains 82.5 g of sugar. Consuming this amount should lead to the
anticipation that vascular endothelial function changes similar to those seen in individuals
in the 75 g post OG'IT study mentioned earlier would occur. This study presents some
evidence to raise awareness of the possible detrimental impacts of a high sugar/high
glucose diet on vascular function.
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